Introduction
Rupture of coronary atherosclerotic plaque and subsequent formation of an occlusive intracoronary thrombus are the major events precipitating acute coronary syndromes [1] [2] [3] [4] [5] [6] . The vulnerable plaque is smaller in size [7] , richer in lipids [1, 2] , and more infiltrated with macrophages [2, 3, [8] [9] [10] than the stable, fibromuscular lesion. Therefore, lowering the lipid and/or macrophage pools stored in the plaque may "stabilize" the plaque and reduce the incidence of plaque rupture [2, [4] [5] [6] . Indeed, cholesterol-lowering trials have yielded a significant reduction in acute cardiac events [11] [12] [13] [14] [15] [16] [17] [18] . Antithrombotic therapies may further prevent acute coronary syndromes by altering the consequences of plaque rupture [4] .
Recent advances in the field of molecular biology, combined with the development of efficient vectors to perform in vivo gene transfer, have led to the emergence of new therapies to prevent acute coronary syndromes. Because gene therapy, in contrast to drug therapy, implies a variable and currently undetermined time interval for the transgene to be expressed, certain gene therapy approaches may ultimately not prove appropriate for treatment of patients with acute infiarction. Genetic interventions that are designed to stabilize the vulnerable plaque and/or to inhibit thrombus formation (Table 40 -1), however, hold considerable promise and are the subject of this review.
Gene Therapy for the Vulnerable Plaque
Lowering the level of plasma cholesterol may reduce the progression, and even induce regression, of atherosclerotic lesions [11] [12] [13] [14] [15] [16] [17] [18] [19] . This result appears to represent the consequence of reducing plasma lowdensity lipoprotein (LDL) levels as well as increasing plasma high-density lipoprotein (HDL) levels. Even modest changes in coronary luminal diameter observed in patients, as a result of lipid-lowering interventions, have been associated with a significant reduction in the incidence of acute coronary syndromes [11] [12] [13] [14] [15] [16] [17] [18] . It is likely that this beneficial effect was due to the regression of plaques rich in cholesterol and macrophages, that is, plaques prone to rupture [4, 19] . Therefore, therapeutic strategies aimed at (1) lowering plasma LDL, (2) increasing plasma HDL, and/or (3) mitigating macrophage infiltration hold promise for reducing the mortality and morbidity associated with coronary atherosclerosis.
FAMILIAL HYPERCHOLESTEROLEMIA: A MODEL FOR LDL-TARGETED GENE THERAPY Familial hypercholesterolemia (FH) is caused by a genetic deficiency in the hepatic receptors for LDL cholesterol and is associated with severe hypercholesterolemia and premature coronary artery disease [20] . The observation that orthotopic liver transplantation from donors who express normal LDL receptor activity may lead to complete correction of the dyslipidemia in homozygotes [21] set the stage for a genetic strategy, first articulated by Goldstein et al. [22] , targeted toward introduction into the liver of normal LDL receptor genes.
Two different approaches to gene therapy have been developed for FH. In the first approach, referred to as ex vivo (or indirect) gene transfer, cells are removed, transduced ex vivo with the LDL receptor gene, then transplanted back into the liver. In the second approach, referred to as in vivo (or direct) gene transfer, the LDL receptor gene is directly introduced into the liver during a one-step procedure. Although FH accounts for only a small minority of patients, the promise of genetically increasing LDL receptor abundance in the liver may have implications for treating more common forms of hypercholesterolemia, and thereby potentially reducing the incidence of acute coronary syndromes in these patients [23] . Based on ~hese eocomagmg results, the firs~ clini ca] rriaI of gerie therapy to Ereae patients with hocnozygous FM was initiated in 1992 [261. In this protocol, an ex wvo approach similar to ~he one used m the WHHL rabbit was adopted. Afker partial hepatectomy, i~epa~ocytes were released and Kansf~ected ex vivo with recombiganr retroviruses expressmg a human LDL-recepeor cDNA. Transduced heparocytes were subsequendy infused directly into d~e portal ciKulatio~ to allow engraftment of LDL ~eceptor-expressing heparocyres in the liver. Preliminary results on the firs~ patient enrolled ir~ this trial were recendv published {2T} The patient tolerated the surgical procedure well. and expression of the transfected LDL receptor gene was documented 4 months after gent ¢ransfer in 1 : l03 to I : [0 a liver cells This was paralleled by a 17% decrease m serum LDL d-xat persisted for ar least l 8 months.
These results, akhough remarkable, require further analysis, Browil et al. have oudincd three maior concerns that remain ~o be addressed before the promise ofge~e therapy for Fli can be fl,lfiHed [28] . First. ir ~ unclear whether the observed reductio~ i~x serum Lf)L was due ro an acruM increase of LDL recepror activity or a reducrion in LDL production in response eo fiver surgery. Study of LDL clearance, rather allan LDL levels, may help to answer this ques~iom Secom]. ir muse be esrablished that the reduction in serum LDL resulted from expression of the exogenous LDL receptor gent, rather than from upregu[atioa of the
